WallStSmart
PRLD

Prelude Therapeutics Inc

NASDAQ: PRLD · HEALTHCARE · BIOTECHNOLOGY

$4.80
+11.48% today

Updated 2026-06-04

Market cap
$314.60M
P/E ratio
P/S ratio
18.77x
EPS (TTM)
$-1.00
Dividend yield
52W range
$1 – $6
Volume
0.4M

Prelude Therapeutics Inc (PRLD) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00$7.00M$12.14M
Revenue growth (YoY)+73.4%
Cost of revenue$149000.00$382000.00$542000.00$2.24M$3.04M$1.17M$1.77M$1.71M
Gross profit$-149000.00$-382000.00$-542000.00$-2.24M$-3.04M$-1.17M$7.00M$10.43M
Gross margin100.0%85.9%
R&D$12.62M$24.28M$48.18M$86.78M$92.89M$103.39M$118.00M$94.30M
SG&A$2.35M$3.83M$10.59M$26.96M$30.65M$28.88M$28.72M$22.41M
Operating income$-14.97M$-28.11M$-58.76M$-113.73M$-123.54M$-132.28M$-139.71M$-104.57M
Operating margin-1995.9%-861.3%
EBITDA$-14.83M$-27.73M$-58.22M$-112.82M$-122.22M$-131.11M$-137.94M$-102.86M
EBITDA margin-1970.6%-847.2%
EBIT$-14.97M$-28.11M$-58.76M$-113.73M$-123.54M$-132.28M$-139.71M$-104.57M
Interest expense$0.00$0.00$0.00$2.04M$1.32M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-14.68M$-27.57M$-56.93M$-110.78M$-107.34M$-121.83M$-127.17M$-99.50M
Net income growth (YoY)-87.8%-106.5%-94.6%+3.1%-13.5%-4.4%+21.8%
Profit margin-1816.8%-819.6%

Frequently asked questions

What is Prelude Therapeutics Inc's revenue?

Prelude Therapeutics Inc's trailing twelve-month revenue is $16.72M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is PRLD?

In its most recent fiscal year, PRLD ran a gross margin of 85.91%, an operating margin of -861.33%, and a net margin of -819.59%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does PRLD generate?

PRLD produced $-56.37M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PRLD's balance sheet healthy?

PRLD holds $35.26M in cash and equivalents against — in long-term debt, on $68.64M of shareholder equity. That debt is best read against the cash flow the business throws off each year.